Epicept Corporation - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Epicept Corporation. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Epicept Corporation. The Group's principal activity is to develop and commercialize pharmaceutical products for the treatment of cancer and pain. The lead product is Ceplene(R), which when used concomitantly with interleukin-2 or IL-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia or AML for adult patients who are in their first complete remission. In addition to Ceplene(R), it has two oncology compounds and a pain product candidate for the treatment of peripheral neuropathies in clinical development. Its cancer portfolio includes Crinobulin, or EPC2407, a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with solid tumors and lymphomas. Its late-stage pain product candidate, EpiCeptTM NP-1 Cream is a prescription topical analgesic cream designed to provide effective long-term relief of pain associated with peripheral neuropathies. It operates in the Unites States and Germany.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report